Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Global Blood Therapeutics stock in Canada | $34.90

Own Global Blood Therapeutics shares in just a few minutes.

Global Blood Therapeutics, Inc
-$0.86 (-3.10%)

Global Blood Therapeutics (GBT) is a leading biotechnology business based in the US. It opened the day at $34.2 after a previous close of $34.13. During the day the price has varied from a low of $33.99 to a high of $35.14. The latest price was $34.9 (25 minute delay). Global Blood Therapeutics is listed on the NASDAQ and employs 389 staff. All prices are listed in US Dollars.

How to buy Global Blood Therapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: GBT in this case.
  5. Research Global Blood Therapeutics stocks. The platform should provide the latest information available.
  6. Buy your Global Blood Therapeutics stocks. It's that simple.

How has Coronavirus impacted Global Blood Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Global Blood Therapeutics's stock price has had significant negative movement.

Its last market close was $38.43, which is 47.13% down on its pre-crash value of $72.69 and 3.96% down on the lowest point reached during the March crash when the stocks fell as low as $39.95.

If you had bought $1,000 worth of Global Blood Therapeutics stocks at the start of February 2020, those stocks would have been worth $683.40 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $583.75.

Global Blood Therapeutics stock price

Use our graph to track the performance of GBT stocks over time.

Global Blood Therapeutics stocks at a glance

Information last updated 2021-07-09.
Previous close$34.13
Change $0.77
Change % 2.2561%
Volume 523,867
Information last updated 2021-07-30.
52-week range$27.1 - $71.23
50-day moving average $34.062
200-day moving average $40.7876
Wall St. target price$78.47
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.645

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Global Blood Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Global Blood Therapeutics price performance over time

Historical closes compared with the last close of $34.9

1 month (2021-07-02) 1.48%
3 months (2021-05-04) -10.47%

Global Blood Therapeutics financials

Revenue TTM USD$148.7 million
Gross profit TTM USD$121.8 million
Return on assets TTM -21.75%
Return on equity TTM -56.26%
Profit margin -167.73%
Book value $5.835
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

How to short and sell Global Blood Therapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "GBT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 12.2 million Global Blood Therapeutics stocks held short by investors – that's known as Global Blood Therapeutics's "short interest". This figure is 2.5% down from 12.5 million last month.

There are a few different ways that this level of interest in shorting Global Blood Therapeutics stocks can be evaluated.

Global Blood Therapeutics's "short interest ratio" (SIR)

Global Blood Therapeutics's "short interest ratio" (SIR) is the quantity of Global Blood Therapeutics stocks currently shorted divided by the average quantity of Global Blood Therapeutics stocks traded daily (recently around 1.5 million). Global Blood Therapeutics's SIR currently stands at 8.13. In other words for every 100,000 Global Blood Therapeutics stocks traded daily on the market, roughly 8130 stocks are currently held short.

However Global Blood Therapeutics's short interest can also be evaluated against the total number of Global Blood Therapeutics stocks, or, against the total number of tradable Global Blood Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Blood Therapeutics's short interest could be expressed as 0.2% of the outstanding stocks (for every 100,000 Global Blood Therapeutics stocks in existence, roughly 200 stocks are currently held short) or 0.2472% of the tradable stocks (for every 100,000 tradable Global Blood Therapeutics stocks, roughly 247 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Global Blood Therapeutics.

Find out more about how you can short Global Blood Therapeutics stock.

Global Blood Therapeutics stock dividends

We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Global Blood Therapeutics stock price volatility

Over the last 12 months, Global Blood Therapeutics's stocks have ranged in value from as little as $27.1 up to $71.23. A popular way to gauge a stock's volatility is its "beta".

GBT.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.031. This would suggest that Global Blood Therapeutics's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Global Blood Therapeutics overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

Stocks similar to Global Blood Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site